1. Home
  2. KALV vs BOC Comparison

KALV vs BOC Comparison

Compare KALV & BOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KALV
  • BOC
  • Stock Information
  • Founded
  • KALV N/A
  • BOC 2009
  • Country
  • KALV United States
  • BOC United States
  • Employees
  • KALV N/A
  • BOC N/A
  • Industry
  • KALV Biotechnology: Pharmaceutical Preparations
  • BOC
  • Sector
  • KALV Health Care
  • BOC
  • Exchange
  • KALV Nasdaq
  • BOC Nasdaq
  • Market Cap
  • KALV 563.1M
  • BOC 448.1M
  • IPO Year
  • KALV N/A
  • BOC 2017
  • Fundamental
  • Price
  • KALV $11.45
  • BOC $14.58
  • Analyst Decision
  • KALV Strong Buy
  • BOC Buy
  • Analyst Count
  • KALV 8
  • BOC 3
  • Target Price
  • KALV $24.83
  • BOC $20.00
  • AVG Volume (30 Days)
  • KALV 567.9K
  • BOC 133.3K
  • Earning Date
  • KALV 03-12-2025
  • BOC 05-13-2025
  • Dividend Yield
  • KALV N/A
  • BOC N/A
  • EPS Growth
  • KALV N/A
  • BOC N/A
  • EPS
  • KALV N/A
  • BOC N/A
  • Revenue
  • KALV N/A
  • BOC $108,274,901.00
  • Revenue This Year
  • KALV N/A
  • BOC $8.51
  • Revenue Next Year
  • KALV N/A
  • BOC $2.21
  • P/E Ratio
  • KALV N/A
  • BOC N/A
  • Revenue Growth
  • KALV N/A
  • BOC 12.49
  • 52 Week Low
  • KALV $7.30
  • BOC $12.41
  • 52 Week High
  • KALV $15.50
  • BOC $16.29
  • Technical
  • Relative Strength Index (RSI)
  • KALV 47.44
  • BOC 53.58
  • Support Level
  • KALV $11.83
  • BOC $13.89
  • Resistance Level
  • KALV $12.50
  • BOC $14.88
  • Average True Range (ATR)
  • KALV 0.58
  • BOC 0.39
  • MACD
  • KALV -0.16
  • BOC 0.08
  • Stochastic Oscillator
  • KALV 19.46
  • BOC 69.57

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

About BOC Boston Omaha Corporation

Boston Omaha Corp is a us-based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. They generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.

Share on Social Networks: